Clinical Trial Update: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and efficacy of IONIS-AGT-LRx in adults with mild hypertension has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• IONIS-AGT-LRx (Angiotensinogen antisense oligonucleotide)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Mild Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2023-01-06